sulfisoxazole diolamine | 4299-60-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: sulfisoxazole diolamine
• 英文别名: 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide;2-(2-hydroxyethylamino)ethanol
• CAS: 4299-60-9
• 化学式: C₄H₁₁NO₂*C₁₁H₁₃N₃O₃S
• 分子量: 372.445
• InChiKey: FEPTXVIRMZIGFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.24
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  159
• 氢给体数：
  5
• 氢受体数：
  9

制备方法与用途

硫异恶唑(磺胺呋喃唑)二乙醇胺是一种内皮素受体拮抗剂，对内皮素受体A和内皮素受体B的IC50值分别为0.60μM和22μM。这种化合物是一种含有恶唑取代基的磺酰胺类抗菌剂，并且通过靶向内皮素受体A抑制乳腺癌外泌体释放。

文献信息

• [EN] FLUOROSILOXANE MATRIX CONTROLLED DIFFUSION DRUG DELIVERY SYSTEM<br/>[FR] SYSTEME D'APPORT DE MEDICAMENT A DIFFUSION REGULEE A MATRICE DE FLUOROSILOXANE
  申请人：BAUSCH & LOMB

  公开号：WO2004000288A1

  公开（公告）日：2003-12-31

  Fluorinated side-chain siloxane copolymeric matrix controlled diffusion drug delivery systems are provided that allow controlled release of sustained concentrations of therapeutic agents within a treated area for a prolonged period of time. The favorable solubility characteristics of the fluorinated sidechains of the siloxane copolymeric matrix controlled diffusion drug delivery systems allow for manipulation of drug release rates depending on the particular therapeutic use and the particular needs of the patient.

  提供了氟化侧链硅氧烷共聚基质控制扩散药物输送系统，允许在治疗区域内控制释放持续浓度的治疗剂，以延长时间。氟化侧链硅氧烷共聚基质控制扩散药物输送系统的有利溶解特性允许根据特定治疗用途和患者特定需求来操纵药物释放速率。
• METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS
  申请人：Wilson Troy Edward

  公开号：US20110269779A1

  公开（公告）日：2011-11-03

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating signal transduction by certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PB kinase in an ocular tissue. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

  本发明提供了能够调节特定蛋白激酶（如mTor、酪氨酸激酶和/或脂质激酶如PB激酶）在眼组织中的信号传导的化学实体或化合物以及其制药组合物。本发明还提供了利用这些组合物调节这些激酶中的一个或多个的活性的方法，特别是用于治疗应用。
• Fatty alcohol drug conjugates
  申请人：——

  公开号：US20020177609A1

  公开（公告）日：2002-11-28

  The invention provides conjugates of fatty alcohols and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparation of the fatty alcohols-pharmaceutical agent conjugates are provided.

  本发明提供了脂肪醇和药物的结合物，可用于治疗癌症、病毒和精神障碍。本发明还提供了脂肪醇-药物结合物的组成、制药制剂和制备方法。
• Alpha gylcosylceramides for treating bacterial and fungal infections
  申请人：——

  公开号：US20020115624A1

  公开（公告）日：2002-08-22

  This invention relates to methods and compositions for the treatment of bacterial or fungal infectious disease, and to methods and compositions for screening assays to select agents that are useful for this purpose. In particular the invention relates to alpha-glycosylceramide molecules and their use in treating such infectious disease.

  本发明涉及用于治疗细菌或真菌感染病的方法和组合物，以及用于筛选筛选试剂的方法和组合物，以选择对此目的有用的试剂。特别地，本发明涉及α-糖基鞘脂分子及其在治疗此类感染病方面的应用。
• Linkage of agents using microparticles
  申请人：Green Howard

  公开号：US20060110379A1

  公开（公告）日：2006-05-25

  Methods, products and kits are provided for attaching agents to a skin surface via microparticles using endogenous or exogenous transglutaminase.

  提供了一种方法、产品和套件，可通过内源或外源性谷氨酰胺转移酶使用微粒子将药剂附着到皮肤表面。